CONTRACTING CELL CULTURE

Transcription

1 CONTRACTING CELL CULTURE

2 BIOTECH EXPERIENCE Page 2

3 Professionals in proteins and antibodies Bayer HealthCare has more than 130 years of experience in developing and producing pharmaceuticals. An integral part of this expertise is the development of biotech products such as recombinant proteins and monoclonal antibodies, which we have successfully pursued for about 20 years. Today our well-established know-how together with our excellent infrastructure open up new opportunities in the area of modern industrial biopharmaceuticals. Our Pharma Biotech Center in Wuppertal (Germany) is well-established as a center of excellence for highly efficient biotech development and manufacturing. Our mammalian cell culture technology based on serum-free cultivation is well suited for biotech product candidates such as glycosylated and non-glycosylated proteins. In summary, we have produced more than 200 target proteins for research as well as more than 10 proteins under cgmp for diagnostic and therapeutic use. AT A GLANCE Highly innovative mammalian cell culture technology Product capture technology Downstream processing to bulk Broad array of protein analytics PRODUCTS Research proteins Diagnostic proteins Preclinical and clinical therapeutic proteins Monoclonal antibodies Recombinant interleukins and muteins Glycosylated and complex proteins Page 3

4 The complete world of fermentation from fed-batch to perfusion We know all aspects of cell cultivation. Whether batch, fed-batch or perfusion fermentation, we choose the best process fitting your special needs. In addition to modern batch and fed-batch technology up to the 200 L scale, our speciality is reliable, high-throughput continuous perfusion fermentation. Our in-house developed inclined plate settlers allow us daily harvesting of L from one single 100 L fermenter. This yields in multiple kilogram quantities of monoclonal antibodies from one unit. In addition, our approach using autoclavable equipment and disposable bags for medium and harvest is highly advantageous regarding flexibility, fast and efficient execution of new projects and, because of the low facility costs, competitive pricing. AT A GLANCE 200 L batch, fed-batch fermentation High-throughput continuous perfusion fermentation (100 L fermenter scale) Broad process know-how Flexible infrastructure Page 4

5 EFFICIENT PRODUCTION PLATE SETTLER PERPETUUM MOBILE FOR SUCCESS Page 5

6 FLEXIBLE PARTNER Page 6

7 Strength of a corporation, flexibility of a start-up Bayer HealthCare is a full service provider for process development and GMP production including all supportive expertise (QA, QC, Compliance, Regulatory Affairs). Our customer base is small and mid-size biotech companies, research and development organizations as well as international pharma companies, since we combine the strength of an established corporation with the advantages of a specialized biotech company. The result: reliable solutions, fast execution and cost-efficient performance. Whether research proteins, preclinical needs, clinical trials, product launch or specific outsourcing, challenge our competence and flexibility. Our compact and flexible technical equipment is ideal for small and mid-size volume products. What we are particularly proud of is our down-to-earth approach. Convince yourself, we are ready to solve your problems. AT A GLANCE Experienced multidisciplinary team Licensed GMP facilities Ideal for outsourcing Focus on small and medium volume products Flexibility of equipment and technology CONTACT US... If you are interested you will find detailed information at or contact us directly. Bayer HealthCare AG Pharma Biotechnology Dr. Berthold Bödeker Wuppertal, Germany Phone: +49 (0)202/ Fax: +49 (0)202/ berthold.boedeker@bayerhealthcare.com Page 7

8 Bayer HealthCare AG Wuppertal Germany Forward-Looking Statements This publication contains forward-looking statements. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of our company and those either expressed or implied by these statements. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). We assume no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. May 2005